View Older Stories View More Recent Stories
-
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
-
Pfizer (PFE) call put ratio 2.2 calls to 1 put with focus on June 28 calls
-
Pfizer's (PFE) BRAFTOVI Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
-
Pfizer (PFE) call put ratio 1 call to 1 put into quarter results
-
Moderna stock rises following RFK Jr's comments
-
Pfizer (PFE) to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
-
Pfizer (PFE) Said To Avoid Challenge From Activist Starboard For Now - Bloomberg
-
Pfizer (PFE) Intends To Sell About 700M Haleon (HLN) Shares
-
Pfizer (PFE) CEO: "all in" on obesity drug development - JPM Healthcare Conference
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Pfizer's (PFE) Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
-
Pfizer (PFE) call put ratio 2.8 calls to 1 put as share price up 1.1%
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
2025 Biopharma sector outlook
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Sangamo Therapeutics (SGMO) to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
-
Pfizer (PFE) Announces FDA Approval of BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
-
Pfizer (PFE) PT Lowered to $32 at Truist Securities
-
Bernstein on Pfizer's (PFE) FY2025 Guide: 'Nothing Too Surprising, But First Guide on Part D IRA Impact'
-
Pfizer (PFE) Reaffirms FY24 Guidance, Issues FY25 Guidance
-
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
-
Pfizer's (PFE) IBRANCE in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast C
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Pfizer (PFE) PT Lowered to $33 at Guggenheim
-
Pfizer (PFE) PT Lowered to $28 at Leerink Partners
-
Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
-
Trump hosted the chief executives of Pfizer (PFE), Eli Lilly & Co. (LLY) - Axios
-
This big pharma stock offers an 'interesting near-term setup' says Morgan Stanley
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
UK's CMA: Competition Appeal Tribunal Fines Pfizer (PFE) and Flynn GBP 69M for Excessive Pricing
-
Pfizer (PFE) Appoints Chris Boshoff as Chief Scientific Officer and President of R&D
-
Pfizer (PFE) Announces EU Approval of HYMPAVZI for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
-
Pfizer (PFE) call put ratio 1 call to 2.3 puts
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
Pfizer (PFE) Explores Sale Of Hospital Drugs Unit, Hires Goldman Sachs For Advice, Sources Say - Reuters
-
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
-
Popular stocks with increasing volume: SOFI DJT F PFE BA MSTR PYPL SMCI SNAP GME
-
Pfizer (PFE) Meeting With Starboard Was Constructive, Cordial - CEO Bourla
-
Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
-
Pfizer (PFE) call put ratio 3.7 calls to 1 put with focus on November 1 weekly calls into quarter results
-
Pfizer (PFE) call put ratio 3.2 calls to 1 put into quarter results
-
Pfizer (PFE): Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
-
Pfizer (PFE) Announces FDA Approval of ABRYSVO for Adults Aged 18 to 59 at Increased RSV Risk
-
Starboard Value Issues Presentation Delivered at 13D Monitor’s 2024 Active-Passive Investor Summit
-
Pfizer (PFE) Appoints Tim Buckley to its Board
-
Pfizer (PFE) Announces FDA Approval of HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
-
UK MHRA: approved an adapted Pfizer (PFE) /BioNTech (BNTX) Covid-19 vaccine (comirnaty) that targets the KP.2 Covid-19 subvariant for adults
-
Pfizer (PFE) call put ratio 3.9 calls to 1 put with focus on October 11 weekly 30 calls
-
Starboard Value Issues Letter to Pfizer’s (PFE) Board of Directors

